Related Experiment Video
Updated: Oct 21, 2025

A Method for Measuring RNA N6-methyladenosine Modifications in Cells and Tissues
Published on: December 5, 2016
RNA N6-methyladenosine demethylase FTO promotes osteoporosis through demethylating Runx2 mRNA and inhibiting
Jing Wang1,2, Qiang Fu3, Jian Yang2
1Department of Orthopedics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Abstract:
As a systemic disease, osteoporosis (OP) results in bone density loss and fracture risk, particularly in the hip and vertebrae. However, the underlying molecular mechanisms of OP development have not been fully illustrated. N6-Methyladenosine (m6A) is the most abundant modification of mRNAs, which is involved in many of pathological processes in aging disease. However, its role and regulatory mechanism in OP remains unknown. Here, we aimed to investigate the roles of m6A and its demethylase FTO in OP development. The results showed that m6A methylated RNA level was up-regulated in the bone marrow mesenchymal stem cells (BMSCs) from patients with OP. The level of N6-methyladenosine demethylase FTO was consistently decreased in the BMSCs from patients with OP. Functionally, lentivirus-mediated FTO overexpression in normal BMSCs to compromised osteogenic potential. Mechanism analysis further suggested that FTO overexpression decreased the m6A methylated and total level of runt related transcription factor 2 (Runx2) mRNA, subsequently inhibited osteogenic differentiation. We found that FTO inhibition could effectively improve the bone formation in ovariectomized osteoporotic mice in vivo. Together, these results reveal that RNA N6-methyladenosine demethylase FTO promotes osteoporosis through demethylating runx2 mRNA and inhibiting osteogenic differentiation.
Insights
The N6-methyladenosine (m6A) demethylase FTO promotes osteoporosis by decreasing Runx2 mRNA levels, inhibiting bone formation. Inhibiting FTO improves bone density in osteoporosis models.
Area of Science:
- Molecular Biology
- Cell Biology
- Biochemistry
Background:
- Osteoporosis (OP) is a systemic disease causing bone density loss and increased fracture risk.
- The molecular mechanisms underlying OP development are not fully understood.
- N6-methyladenosine (m6A) modification is implicated in aging diseases, but its role in OP is unknown.
Purpose of the Study:
- To investigate the roles of m6A and its demethylase FTO in osteoporosis development.
- To elucidate the regulatory mechanisms of FTO in bone metabolism.
Main Methods:
- Analysis of m6A levels and FTO expression in bone marrow mesenchymal stem cells (BMSCs) from OP patients.
- Overexpression of FTO in normal BMSCs using lentivirus.
- Assessment of osteogenic differentiation potential.
- In vivo studies using ovariectomized osteoporotic mice.
Main Results:
- m6A RNA levels were elevated, while FTO levels were decreased in BMSCs from OP patients.
- FTO overexpression in normal BMSCs compromised osteogenic potential.
- FTO overexpression reduced m6A-modified and total Runx2 mRNA levels, inhibiting osteogenic differentiation.
- FTO inhibition improved bone formation in vivo in an OP mouse model.
Conclusions:
- RNA N6-methyladenosine demethylase FTO promotes osteoporosis.
- FTO exerts its effect by demethylating Runx2 mRNA and inhibiting osteogenic differentiation.
- Targeting FTO may offer a therapeutic strategy for osteoporosis.
More Related Videos
Related Concept Videos
Master Transcription Regulators
RNA Stability
Epigenetic Regulation
X-chromosome...
Nuclear Export of mRNA
Abnormal Proliferation
MicroRNAs

